3
Announcements
Trials
Browse
Landscape
Status
Available
1
Sponsor Class
INDUSTRY
1
Study Type
Expanded_access
1
Sponsor
Cancer Type
Lymphoid
2
Other hematologic neoplasm
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
11
Burkitt Lymphoma
4
Recurrence
3
Lymphoma, Large B-Cell, Diffuse
3
Leukemia
3
Neoplasm, Residual
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Interventions
Cyclophosphamide
217
fludarabine phosphate
120
Rituximab
108
Filgrastim
100
Peripheral Blood Stem Cell Transplantation
86
Etoposide
83
fludarabine
80
Busulfan
80
Radiotherapy
76
Tacrolimus
73
Methotrexate
73
Melphalan
71
Mycophenolic Acid
70
Cytarabine
65
Antilymphocyte Serum
61
Whole-Body Irradiation
56
Cyclosporine
54
Vincristine
49
Prednisone
42
Doxorubicin
41
Methylprednisolone
34
Granulocyte Colony-Stimulating Factor
34
Dexamethasone
30
Cord Blood Stem Cell Transplantation
29
sargramostim
27
Alemtuzumab
26
Stem Cell Transplantation
24
Carmustine
24
Thiotepa
23
thymoglobulin
21
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphoma
×
tisagenlecleucel
×
Other hematologic neoplasm
×
Clear all
NCT03601442
2026-04-23
Managed Access Programs for CTL019, Tisagenlecleucel
Novartis
Available